British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...

This includes building on the momentum from the U.S. launch of Livdelzi for primary biliary cholangitis and preparing for the ...

Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented ...

Ipsen presents three late-breaking presentations and eight abstracts across rare cholestatic liver disease portfolio at AASLD 2024Elafibranor was granted marketing authorisation for the treatment of ...

RTY-694 increased protein levels and function of ABCB4 and BSEP in primary hepatocytes, two transporters that play a key role in bile composition ...

Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected ...

KDEV) today announces that its portfolio company Umecrine Cognition will present data from a recent interim analysis from an ongoing Phase 1b/2a clinical study of golexanolone in patients with Primary ...